Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
НИИ фармакологии им. В.В.Закусова, РАМН
Список исп. литературыСкрыть список 1. Александровский Ю.А. Зависимость действия транквилизаторов от некоторых особенностей структуры личности у больных с пограничными состояниями. Журн. невропатол. и психиатр. им. С.С.Корсакова. 1984; 34 (9): 1367–76. 2. Вальдман А.В. Психофармакотерапия невротических расстройств. М.: Медицина, 1987. 3. Вальдман А.В. Фармакологическая регуляция эмоционального стресса. М.: Медицина, 1979. 4. Влияние мембраномодулятора 3-оксипиридина на эмоционально-стрессовую реакцию и связывание Н3-диазепама в мозге инбредных мышей. Под ред. С.Б.Середенина, Ю.А.Бледнова, М.Л.Гордей и др. Хим.-фармацевт. журн. 1987; 2: 134–7. 5. Воронин М.В. Сигма- (s)-рецептор – потенциальная мишень для селективных анксиолитиков. Материалы 5-й Международной конференции «Биологические основы индивидуальной чувствительности к психотропным средствам». М.: Фолиум, 2010; с. 9. 6. Воронина Т.А. Фармакология соединений бензодиазепинового ряда. Автореф. дис. … д-ра мед. наук. М., 1978. 7. Воронина Т.А. Антиоксидант мексидол. Основные нейропсихотропные эффекты и механизм действия. Психофармакология. Биол. наркология. 2001; 1 (1): 2–12. 8. Воронина Т.А. Влияние мембраномодулятора из класса 3-оксипиридина на фармакологическую активность психотропных препаратов. Бюл. эксперим. биологии и медицины. 1985; 99 (5): 519–22. 9. Воронина Т.А. Перспективы поиска новых анксиолитиков. Эксперим. и клин. фармакология. 2002; 5: 4–17. 10. Гришин С.А. Клинико-фармакологическая характеристика ладастена в качестве антиастенического средства. Автореф. дис. … канд. мед. наук. М., 2008. 11. Гурович И.Я. Психическое здоровье населения и психиатрическая помощь в России. Соц. и клин. психиатрия. 2001; 11 (1): 9–15. 12. Дюмаев К.М. Антиоксиданты в профилактике и терапии патологии ЦНС. М.: Изд-во ИБХ РАМН, 1995. 13. Закусов В.В. Новые доказательства ГАМКергического компонента в механизме действия бензодиазепиновых транквилизаторов. Бюл. эксперим. биологии и медицины. 1981; 5: 571–4. 14. Клинический анализ терапевтического действия и эффективности гидазепама. Г.Г.Незнамов, С.И.Лыгалов, В.К.Бочкарев и др. Гидазепам. Под. ред. С.А.Андронати. Киев: Наукова думка, 1992; с. 137–51. 15. Незнамов Г.Г. Клинико-фармакологический анализ транквилизирующего действия мексидола. Бюл. Всесоюзного научного центра по безопасности биологически активных веществ. 1992; с. 47–54. 16. Прогноз индивидуальных реакций на эмоциональный стресс и бензодиазепиновые транквилизаторы. С.Б.Середенин, Б.А.Бадыштов, Г.Г.Незнамов и др. Эксперим. и клин. фармакология. 2001; 64 (1): 3–12. 17. Результаты клинического изучения селективного анксиолитика афобазола. Г.Г.Незнамов, С.А.Сюняков, Д.В.Чумаков и др. Эксперим. и клин. фармакология. 2001; 64 (2): 15–9. 18. Рохлина М.Л. Наркомании и токсикомании. Руководство по психиатрии. Под ред. А.С.Тиганова. Т. 2. М.: Медицина, 1999; с. 339–427. 19. Селье Г. Стресс без дистресса. М.: Прогресс, 1979. 20. Середенин С.Б. Влияние психотропных препаратов на поведение инбредных мышей в условиях эмоционального стресса. Бюл. эксперим. биологии и медицины. 1979; 6: 76–89. 21. Середенин С.Б. Лекции по фармакогенетике. М.: МИА, 2004. 22. Середенин С.Б. Создание новых анксиолитиков с позиций мультифакториального контроля тревожных реакций. Психофармакология и биол. наркология. 2007; 7. Спец. вып. Материалы III съезда фармакологов России. Фармакология – практическому здравоохранению. Ч. 2. СПб.; с. 1944. 23. Смулевич А.Б. Аффективные заболевания непсихотического уров-ня – циклотимия, дистимия. Руководство по психиатрии. Под ред. А.С.Тиганова. Т. 2. М.: Медицина, 1999; с. 608–35. 24. Смулевич А.Б. Транквилизаторы – производные бензодиазепина в психиатрии и общей медицине. М.: Медиа Сфера, 1999. 25. Стандарты оказания помощи больным шизофренией. Под ред. В.Н.Краснова, И.Я.Гуровича, С.Н.Мосолова и др. М.: МНИИ психиатрии Росздрава, 2006. 26. Фармакогенетическая концепция анксиолитического эффекта. С.Б.Середенин, Т.А.Воронина, Г.Г.Незнамов и др. Вестн. АМН. 1998; 11: 47–52. 27. Фармакогенетическое исследование анксиолитических свойств новых антагонистов холецистокининовых рецепторов у животных с различным уровнем эмоциональности. Л.Г.Колик, Т.А.Гудашева, С.Б.Середенин и др. Бюл. эксперим. биологии и медицины. 2003; 135 (5): 519–23. 28. Фармакоэпидемиологический анализ амбулаторного назначения транквилизаторов группы бензодиазепина в психиатрических учреждениях. А.С.Аведисова, Д.В.Ястребов, Е.А.Костачева и др. Рос. психиатр. журн. 2005; 4: 10–2. 29. Феназепам: 25 лет в медицинской практике. С.Б.Середенин, Т.А.Воронина, Г.Г.Незнамов и др. М.: Наука, 2007. 30. Чумаков Д.В. Клинико-фармакологическая характеристика нового анксиолитика афобазола. Автореф. дис. … канд. мед. наук. М., 2004. 31. Яркова М.А. Изучение анксиолитических свойств производных 2-меркаптобензимидазола. Автореф. дис. … канд. мед. наук. М., 1996. 32. A pilot controlled trial of bupropion XL vs. escitalopram in generalized anxiety disorder (GAD). A.Bystritsky, L.Kerwin, J.Feusner, T.Vapnik. Psychopharmacol Bull 2008; 41 (1): 1–9. 33. Adaptative and maladaptative psychobiological responses to severe psychological stress: implications for the discovery of novel pharmacotherapy. O.Bonne, C.Grillon, M.Vythilingam et al. Neuroscience and Biobehavior Rev 2004; 28: 65–94. 34. Aggressive behavior and altered amount of brain serotonin and norepinephrine in mice lacking MAO A. O.Cases, I.Seif, J.Grimsby et al. Science 1995; 268: 1763–6. 35. Altered 5-HT1A binding in panic disorder demonstrated by positron emission tomography. J.Nash, P.Sargent, E.Rabiner et al. Eur Neuropsychopharmacol 2004; 14 (Suppl. 3): 322–3. 36. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone and diazepam. K.Rickels, R.Downing, E.Schweizer, H.Hassman. Arch Gen Psychiat 1993; 50 (11): 884–95. 37. Argyropoulos SV. The psychobiology of anxiolytic drugs. Part 2: pharmacological treatments of anxiety. Pharmacol Ther 2000; 88: 213–27. 38. Association between catechol-O-methyltransferase and phobic anxiety. M.McGrath, I.Kawachi, A.Ascherio et al. Am J Psychiat 2004; 161 (9): 1703–5. 39. Bäckman U. Stockholm concentrates on decentralization. Increased outpatient care in psychiatry. Vardfacket 1980; 4 (4): 59–61. 40. Baldwin DS. Role of pregabalin in the treatment of generalized anxiety disorder. Neuropsychiat Dis Treat 2007; 3 (2): 185–91. 41. Barlow DH. Anxiety and its disorders: the nature and treatment of anxiety and panic. NY: Guilford Press 2002. 42. Behavioral, neurochemical, anatomical and electropysiological correlates of panic disorder: múltiple transmitter interaction and neuropeptide colocalization. R.Zacharko, D.Koszycki, P.Mendella, J.Bradwejn. Prog Neuro Biol 1995; 47 (4–5): 371–423. 43. Benzodiazepine use in older adults enrolled in a health maintenance organization. S.Gray, A.Eggen, D.Blough et al. Am J Geriatr Psychiat 2003; 11 (5): 568–76. 44. Benzodiazepines: revisiting clinical issues in treating anxiety disorders. J.Rosenbaum, C.O\'Brien, M.Otto et al. J Clin Psychiat 2005; 7 (1): 23–31. 45. Blalock JE. The syntax of immune-neuroendocrine communication. Immunol Tod 1994; 15: 504–11. 46. Bourin M. Neurobiology of panic disorder. J Psychosom Res 1998; 44: 163–80. 47. British National Formulary №31. British Medical association and Royal pharmaceutical society of Great Britain. London 1996; p. 700. 48. Charney DS. Serotonin function in anxiety: effects of serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacol 1987; 92 (1): 14–24. 49. Chest pain: relationship of psychiatric illness to coronary arteriographic results. W.Katon, M.Hall, J.Russo et al. Am J Med 1988; 84 (1): 1–9. 50. Conner KM. Treatment of generalized anxiety disorder: current options and future developments. Effective recognition and treatment of generalized anxiety disorder in primary care. J Clin Psychiat 2004; 6: 35–41. 51. Correlates and prevalence of benzodiazepine use in community-dwelling elderly. P.Gleason, R.Schulz, N.Smith et al. J Gen Intern Med 1998; 13 (4): 243–50. 52. Coryell W. Mortality among outpatients with anxiety disorders. Am J Psychiat 1986; 143 (4): 508–10. 53. CSF serotonin: diagnostic and seasonal differences. T.Brewerton, R.Lydiard, M.Johnson et al. Biol Psychiat 1995; 37 (9): 655–65. 54. Decreased benzodiazepine receptor binding in panic disorder measured by lomazenil-SPECT. S.Schlegel, H.Steinert, A.Bocksich et al. Eur Arch Psychiat Clin Neurosci 1994; 244 (1): 49–51. 55. Decreased brain GABA (A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET-study. A.Malizia, V.Cunningham, C.Bell et al. Arch Gen Psychiat 1998; 55 (8): 715–20. 56. Decreased GABA-A-receptor clustering results in enhanced anxiety and a bias for threat cues. F.Crestani, M.Lorez, K.Baer et al. Nat Neurosci 1999; 2 (9): 833–9. 57. Den Boer JA. Behavioral, neuroendocrine and biochemical effects of 5-hydroxytryptophan administration in panic disorder. Psychiat Res 1990; 31 (3): 267–78. 58. Den Boer JA. Serotonin function in panic disorder: a double-blind placebo study with fluvoxamine and ritanserin in patients with panic disorder. Psychopharmacol 1990; 102 (1): 85–94. 59. Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. H.Wittchen, R.Carter, H.Pfister et al. Int Clin Psychopharmacol 2000; 15 (6): 319–28. 60. Distressed high utilizers of medical care: DSM-III-R diagnoses and treatment needs. W.Katon, M. von Korff, E.Lin et al. Gen Hospital Psychiat 1990; 12 (6): 355–62. 61. Dopamine and antianxiety activity. D.Taylor, L.Riblet, H.Stanton et al. Pharmacol Biochem Behavior 1982; 17 (Suppl. 1): 25–35. 62. Effects of L-741, 741, a selective dopamine receptor antagonist, on anxiety tested in the elevated plus-maze in mice. J.Navarro, G.Luna, F.Garcia, C.Pedraza. Meth Find Exp Clin Pharmacol 2003; 25 (1): 45–7. 63. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. R.Pohl, D.Feltner, R.Fieve, A.Pande. J Clin Psychopharmacol 2005; 25 (2): 151–8. 64. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. D.Baldwin, I.Anderson, D.Nutt et al. J Psychopharmacol 2005; 19: 567–96. 65. Eysenck HJ. Experiments with drugs. Studies in the relation between personality, learning theory and drug action. Oxford: Permagon Press 1963. 66. Factors predicting the clinical course of generalised anxiety disorder. K.Yonkers, I.Dyck, M.Warshaw, M.Keller. Br J Psychiat 2000; 176 (6): 544–9. 67. Finn DA. Genetic animal models of anxiety. Neurogenet 2003; 4 (3): 109–35. 68. Fricchione G. Generalized anxiety disorder. N Engl J Med 2004; 351 (7): 675–82. 69. Genetic difference in sensitivity to beta-carboline: evidence for the involvement of brain benzodiazepine receptors. G.Chapouthier, D.Bondoux, B.Martin et al. Brain Res 1991; 553 (2): 342–6. 70. Graeff FG. Serotonin, the periaqueductal gray and panic. Neurosci Biobehavior 2004; 28 (3): 239–59. 71. Health care costs associated with depressive and anxiety disorders in primary care. G.Simon, J.Ormel, M. von Korff, W.Barlow. Am J Psychiat 1995; 152 (3): 352–7. 72. Health related quality of life in primary care patients with mental disorders: results from the PRIME MD 1000 Study. R.Spitzer, K.Kroenke, M.Linzer et al. J Am Med Associat 1995; 274 (19): 1511–7. 73. Hirschfeld RM. Placebo response in the treatment of panic disorder. Bull Menning Clin 1996; 60 (2): 76–86. 74. Hofmann SG. The costs of anxiety disorders: implications for psychosocial interventions. Cost-effectiveness of psychotherapy: a guide for practitioners, researchers, and policymakers. NY: Oxford University Press 1999; p. 224–34. 75. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. R.Kessler, R. Du Pont, P.Berglund, H.Wittchen. Am J Psychiat 1999; 156 (12): 1915–23. 76. Increased anxiety and altered responses to anxiolytics in mice deficient in the 65-k Da isoform of glutamic acid decarboxylase. S.Kash, L.Tecott, C.Hodge, S.Baekkeskov. Proc Natl Acad Sci USA 1999; 96 (4): 1698–703. 77. Joëls M. The neuro-symphony of stress. Nat Rev Neurosci 2009; 10 (6): 459–66. 78. Kahn RS. L-5-hydroxytryptophan in the treatment of anxiety disorders. J Affect Disord 1985; 8 (2): 197–200. 79. Kaschka W. Reduced benzodiazepine receptor binding in panic disorder measured by iomazenil SPECT. J Psychiat Res 1995; 29 (5): 447–534. 80. Keller MB. The clinical course of panic disorder and depression. J Clin Psychiat 1992; 53 (Suppl.): 5–8. 81. Kessler RC. The epidemiology of generalized anxiety disorder. Psychiat Clin North Am 2001; 24 (1): 19–39. 82. Kotlinska J. A characterization of anxiolytic-like actions induced by the novel NMDA/glycine site antagonist. Psychopharmacol 1998; 135 (2): 175–81. 83. Leon AC. The social costs of anxiety disorders. Brit J Psychiat 1995; 166 (Suppl. 27): 19–22. 84. Lesch KP. Molecular foundation of anxiety disorders. J Neural Transm 2001; 108 (6): 717–46. 85. Marks I. Anxiety states (anxiety neurosis): a review. J Nerv and Ment Disease 1973; 156 (1): 3–18. 86. Maron E. Serotonin function in panic disorder: important, but why? Neuropsychopharmacol 2006; 31 (1): 1–11. 87. Massion A. Quality of life and psychiatric morbidity in panic disorder and generalized anxiety disorder. Am J Psychiat 1993; 150 (4): 600–7. 88. McEwen B. Stress and the nervous system: introduction. Seminars in the Neuroscienc 1994; 6 (4): 195–6. 89. Mental health in Europe (country reports from the WHO European network on mental health). World Health Organization 2001. 90. Nashold BS. The midbrain and pain. Advances in neurology: international symposium on pain. NY: Raven Press 1974; 4: 191–6. 91. Neuroanatomical hypothesis of panic disorder, revised. J.Gorman, J.Kent, G.Sullivan et al. Am J Psychiat 2000; 157 (4): 493–505. 92. Neurobiology of anxiety (II): childhood anxiety, generalized anxiety disorder and mixed anxiety-depressive disorder. F.Nieto-Escámez, G.López-Crespo, L.Roldán-Tapia, F.Cañadas-Pérez. Antidepressants, antipsychotics, anxiolytics from chemistry and pharmacology to clinical application. Weinheim: WILEY-VCH Verlag GmbH & Co 2007; p. 761–802. 93. Newport DJ. Neurobiology of posttraumatic stress disorder. Curr Opin Neur Biol 2000; 10 (2): 211–8. 94. Ng R. Drugs: from discovery to approval. Hoboken: John Wiley & Sons 2004. 95. Noyes R. Anxiety neurosis: a 5-year follow-up. J Nerv and Ment Disease 1976; 162 (3): 200–5. 96. Nutt DJ. Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectr 2005; 10 (1): 49–56. 97. Nutt DJ. The neurochemistry of anxiety: an update. Prog Neuropyschopharmacol Biol Psychiat 1990; 14 (5): 737–52. 98. Palkovits M. Peptidergic transmitter systems. Biologic Psychiat 2002; 1: 85–95. 99. Panic-induced elevation of plasma MHGP levels in phobic-anxious patients: effects of clonidine and imipramine. G.Ko, J.Elsworth, R.Roth et al. Arch Gen Psychiat 1983; 40 (4): 425–30. 100. Panksepp J. The future of neuropeptides in biological psychiatry and emotional psychopharmacology: goals and strategies. Hoboken, New Jersey: John Wiley & Sons 2004; p. 627–60. 101. Panksepp J. Toward a general psychobiological theory of emotions. Behavior and Brain Scienc 1982; 5 (3): 407–22. 102. Parker G. Early onset depression: the relevance of anxiety. Soc Psychiat Epid 1997; 32 (1): 30–7. 103. Personality and benzodiazepine sensitivity in anxious patients and control subjects. D.Cowley, P.Roy-Byrne, D.Greenblatt et al. Psychiat Res 1993; 47 (2): 151–62. 104. Phenomenology and course of generalised anxiety disorder. K.Yonkers, M.Warshaw, A.Massion, M.Keller. Br J Psychiat 1996; 168 (3): 308–13. 105. Plutchik R. Emotion: a psychoevolutionary synthesis. NY: Harper & Row 1980. 106. Pratt JA. The neuroanatomical basis of anxiety. Pharmacol Ther 1992; 55 (2): 149–81. 107. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. K.Rickels, M.Pollack, D.Feltner et al. Arch Gen Psychiat 2005; 62 (9): 1022–30. 108. Prospective study of phobic anxiety and risk of coronary heart disease in men. I.Kawachi, G.Colditz, A.Ascherio et al. Circulat 1994; 89 (5): 1992–7. 109. Reduced benzodiazepine receptor sensitivity in panic disorder. P.Roy-Byrne, D.Cowley, D.Greenblatt et al. Arch Gen Psychiat 1990; 47 (6): 534–8. 110. Reduced brain serotonin transporter binding in patients with panic disorder. E.Maron, J.Kuikka, J.Shilk et al. Psychiat Res 2004; 132 (2): 173–81. 111. Reduced serotonin type 1A-receptor binding in panic disorder. A.Neumeister, E.Bain, A.Nugent et al. J Neurosci 2004; 24 (3): 589–91. 112. Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy. A.Goddard, G.Mason, A.Almai et al. Arch Gen Psychiat 2001; 58 (6): 556–61. 113. Relationship of generalized anxiety symptoms to urinary 5-hydroxyindoleacetic acid and vanillylmandelic acid. M.Garvey, R.Noyes, C.Woodman, C.Laukes. Psychiat Res 1995; 57 (1): 1–5. 114. Report of benzodiazepine Committee. Department of Health and Children. Dublin 2002. 115. Ressler KJ. Peptides and psychiatry. International encyclopedia of the social & behavioral sciences. Elsev Science Ltd 2001; p. 11 189–95. 116. Rice DP. The economic burden of mental disorders. Advances in health Economics and Health Services Research 1993; 14: 37–53. 117. Robertson HA. Benzodiazepine receptors in «emotional» and «non-emotional» mice: comparison of four strains. Eur J Pharmacol 1979; 56 (1–2): 163–6. 118. Roy-Byrne PP. Anxiety management in the medical setting: rationale, barriers to diagnosis and treatment, and proposed solutions. The management of stress and anxiety in medical disorders. D.Mostofsky, D.Barlow. Boston: Allyn & Bacon 2000; p. 1–14. 119. Roy-Byrne PP. Course and outcome in panic disorder: a review of recent follow-up studies. Anxiety 1995; 1 (4): 151–60. 120. Roy-Byrne PP. Generalized anxiety disorder in primary care: the precursor/modifier pathway to increased health care utilization. J Clin Psychiat 1997; 58 (Suppl. 3): 34–8. 121. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole. M.Millan, M.Brocco, M.Papp et al. J Pharmacol Exp Ther 2004; 309 (3): 936–50. 122. Schatzberg AF. Textbook of psychopharmacology. 4th ed. Washington DC: Am Psychiat Publish 2009. 123. Schramm NL. The alpha (2a)-adrenergic receptor plays a protective role in mouse behavioral models of depression and anxiety. J Neurosci 2001; 21 (13): 4875–82. 124. Seredenin SB. A pharmacogenetic approach to the design of new selective anxiolytic drugs. Biological basis of individual sensitivity to psychotropic drugs. Edinburgh 1995; p. 25–38. 125. Single neuron analysis of the human midbrain tegmentum. Rostral mecencephalic reticulotomy for pain relief. K.Amaro, T.Tanikawa, H.Iseki et al. Appl Neuroph 1978; 41: 66–78. 126. Sramek JJ. Generalised anxiety disorder: treatment options. Drugs 2002; 62 (11): 1635–48. 127. Strand FL. Neuropeptides. Handbook of contemporary neuropharmacology. D.Sibley, I.Hanin, M.Kuhar, P.Skolnick. Hoboken, New Jersey: John Wiley & Sons 2007; 1: 669–705. 128. Suicidal ideation and suicide attempts in panic disorder and attacks. M.Weissman, G.Klerman, J.Markowitz, R.Ouellette. New Eng J Med 1989; 321 (18): 1209–14. 129. Sussman N. Pharmacotherapy for generalized anxiety disorder. Textbook of anxiety disorders. Washington, DC. Am Psychiat Press 2002; p. 135–40. 130. The current state of mental health care in Italy: problems, perspectives, and lessons to learn. G. de Girolamo, M.Bassi, G.Neri et al. Eur Arch Psychiat Clin Neurosci 2007; 257 (2): 83–91. 131. The economic burden of anxiety disorders in the 1990. P.Greenberg, T.Sisitsky, R.Kessler et al. J Clin Psychiat 1999; 60 (7): 427–35. 132. The prognosis of anxiety neurosis. R.Noyes, Jr.Clancy, P.Hoenk, D.Slymen. Arch Gen Psychiat 1980; 37 (2): 173–8. 133. Tiihonen J. Cerebral benzodiazepine receptor dinding and distribution in GAD: a fractal analysis. Mol Psychiat 1997; 2 (6): 463–71. 134. Toth M. Neurobiology of anxiety. Handbook of contemporary neuropharmacology. D.Sibley, I.Hanin, M.Kuhar, P.Skolnick. Hoboken, New Jersey. John Wiley & Sons 2007; 2: 3–57. 135. Van der Kar LD. Forebrain pathways mediating stress-induced hormone secretion. Front in Neuroendocrinol 1999; 20 (1): 1–48. 136. Van Hulten R. Usage patterns of benzodiazepines in a Dutch community: a 10-year follow-up. Pharmacy World & Science 1998; 20 (2): 78–82. 137. Voronina TA. Analysis of the mechanism of psychotropic action of 3-hydroxypyridine derivative. Ann Ist Super Sanita 1988; 24 (3): 461–6. 138. Wegener C. Molecular evolution of neuropeptides in the genus Drosophila. Genome Biol 2008; 9 (8). 139. Weizman R. Peripheral benzodiazepine binding sites on platelet membranes are increased during diazepam treatment of anxious patients. Eur J Pharmacol 1987; 138 (2): 289–92. 140. Why do people with anxiety disorders become depressed? A prospective-longitudinal community study. H.Wittchen, R.Kessler, H.Pfister, M.Lieb. Act Psychiat Scand Suppl 2000; 406: 14–23. 141. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety. Obsessive-compulsive and posttraumatic stress disorders. B.Bandelow, J.Zohar, E.Hollander et al. World J Biol Psychiat 2002; 3: 171–99. 142. Timmerman W, Ciscki G, Nap A, De Vries. Effects of handling on extracellular levels of glutamate and other amino acids in various areas of the brain measured by microdialysis. Brain Res 1999; 833: 150–60. 143. Molchanov ML, Guimaraes FS. Anxiolytic‐like effects of AP7 injected into the dorsolateral and ventrolateral columns of the periaqueductal grey of rats. Psychopharmacol 2002; 160: 30–8. 144. Kubo T, Okatani H, Kanaya T et al. Cholinergic mechanism in the lateral septal area is involved in the stress‐induced blood pressure increase in rats. Brain Res Bull 2003; 59: 359–64. 145. Salas R, Pier F, Fung B et al. Altered anxiety‐related responses in mutant mice lacking the b4 subunit of the nicotinic receptor. Soc Neurosci Abstr 2002; 283: 6. 146. Poelchen W, Sieler D, Wirkner K, Illes P. Co‐transmitter function of ATP in central catecholamine neurons of the rat. Neurosci 2001; 102: 593–602. 147. Van BF, Verkes RJ. Neurosteroids in depression: a review. Psychopharmacol 2003, 165: 97–110. 148. Koponen H, Allgulander C et al. Efficacy of duloxetine for the treatment of anxiety disorder: implication for primary care. J Clin Psychiat 2007; 9 (2): 100–7. 149. Black DW. Efficacy of combined pharmacotherapy and psychotherapy versus monotherapy in the treatment of anxiety disorders. CNS Spectr 2006; 11 (10 Suppl. 12): 29–33. 150. Nutt DJ. Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectr 2005; 10 (1): 49–56. 151. Black K, Shea C, Dursun S, Kutcher S. Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. J Psychiat Neurosci 2000; 25 (3): 255–61. 152. Kessler RC, Chiu WT, Demler O et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiat 2005; 62 (6): 617–27. 153. Kessler RC, Berglund P, Demler O et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiat 2005; 62 (6): 593–602. 154. The size and burden of mental disorders and other disorders of the brain in Europe 2010. H.Wittchen, F.Jacobi, J.Rehm et al. Eur Neuropsychopharmacol 2011; 21 (9): 655–79. 155. Кост Н.В., Мешавкин В.К., Зозуля А.А. Нейропептиды в регуляции тревоги. Психиатрия. 2010; 46 (4): 64–75. 156. Dooley DJ, Mieske CA, Borosky SA. Inhibition of K+-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett 2000; 280: 107–10. 157. Dooley DJ, Donovan CM, Pugsley TA. Stimulus-dependent modulation of [3H] norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther 2000; 295: 1086–93. 158. Fehrenbacher JC, Taylor CP, Vasko MR. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 2003; 105: 133–41. 159. Geracioti TD, Carpenter LL, Owens MJ et al. Elevated cerebrospinal fluid substance P concentrations in posttraumatic stress disorder and major depression. Am J Psychiat 2006; 163: 637–43. 160. Di Guilmi MN, Urbano FJ, Inchauspe CG, Uchitel OD. Pregabalin modulation of neurotransmitter release is mediated by change in intrinsic activation/inactivation properties of ca (v) 2.1 calcium channels. J Pharmacol Exp Ther 2011; 336 (3): 973–82. 161. Fink K, Dooley DJ, Meder WP et al. Inhibition of neuronal Ca2+-influx by gabapentin and pregabalin in the human neocortex. Neuropharmacol 2002; 42: 229–36. 162. Вельтищев Д.Ю., Марченко А.С. Генерализованное тревожное расстройство: эпидемиология, патогенез, диагностика и фармакотерапия (обзор литературы). Псих. расстройства в общей медицине. 2011; 1: 56–64. 163. Feltner DE, Crockatt JG, Dubovsky SJ et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003; 23: 240–9. 164. Pande AC, Crockatt JG, Feltner DE et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiat 2003; 160: 533–40. 165. Montgomery SA, Tobias K, Zornberg GL et al. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiat 2006; 67: 771–82. 166. Kasper S, Herman B, Nivoli G et al. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol 2009; 24 (2): 87–96. 167. Lydiard RB, Rickels K, Herman B et al. Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. Int J Neuropsychopharmacol 2010; 13 (2): 229–41. 168. Weaver J, Micely J, Shiovitz T et al. Adjunctive pregabalin after partial response to SSRI or SNRI in GAD: results of double-blind, placebo-controlled trial. Eur Neuropsychopharmacol 2009; 19: 593. 169. Bandelow B, Zohar J, Hollander E et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – 1st revision. World J Biol Psychiat 2008; 9 (4): 248–312. 170. Arnold LM, Zlateva G, Sadosky A et al. Correlations between fibromyalgia symptom and function domains and patient global impression of change: a pooled analysis of three randomized, placebo-controlled trials of pregabalin. Pain Med 2011; 12 (2): 260–7. 171. Straube S, Moore RA, Paine J et al. Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response. BMC Musculoskelet Dis 2011; 12: 125. 172. Boschen MJ. A meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorder. Can J Psychiat 2011; 56 (9): 558–66. 173. Härmark L, Puijenbroek E, Grootheest K. Longitudinal monitoring of the safety of drugs by using a web-based system: the case of pregabalin. Pharmacoepidemiol Drug Saf 2011; 20 (6): 591–7. 174. Nutt D, Mandel F, Baldinetti F. Early onset anxiolytic efficacy after a single dose of pregabalin: double-blind, placebo- and active-comparator controlled evaluation using a dental anxiety model. J Psychopharmacol 2009; 23 (8): 867–73. 175. Rizzato B, Leone G, Misaggi G et al. Efficacy and tolerability of pregabalin versus topiramate in the prophylaxis of chronic daily headache with analgesic overuse: an open-label prospective study. Clin Neuropharmacol 2011; 34 (2): 74–8. 176. Trinkley KE, Nahata MC. Treatment of irritable bowel syndrome. J Clin Pharm Ther 2011; 36 (3): 275–82. 177. Gale JD, Houghton LA. Alpha 2 Delta (a2d) ligands, gabapentin and pregabalin: what is the evidence for potential use of these ligands in irritable bowel syndrome. Front Pharmacol 2011; 2: 28. 178. Allen R, Chen C, Soaita A et al. A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. Sleep Med 2010; 11 (6): 512–9. 179. Feltner DE, Liu-Dumaw M, Schweizer E, Bielski R. Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study. Int Clin Psychopharmacol 2011; 26 (4): 213–20. 180. Oulis P, Mourikis I, Konstantakopoulos G. Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder. Int Clin Psychopharmacol 2011; 26 (4): 221–4. 181. Зозуля А.А., Незнамов Г.Г., Сюняков Т.С. и др. Эффективность и возможные механизмы действия нового пептидного анксиолитика селанка при терапии генерализованного тревожного расстройства и неврастении. Журн. неврол. и психиатр. им. C.C.Корсакова. 2008; 108 (4): 38–48. 182. Дорофеева О.А. Клинико-фармакологические закономерности терапевтического действия разных лекарственных форм феназепама у больных с тревожными расстройствами. Автореф. дис. … канд. мед. наук. М., 2009. 183. Романов Д.В. Этифоксин (Стрезам) в современной терапии тревожных расстройств (обзор зарубежной и отечественной литературы). Психиатр. и психофармакотер. 2010; 6: 13–7. 184. Schatzberg AF, Haddad P, Kaplan EM et al. Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Discontinuation consensus panel. J Clin Psychiat 1997; 58 (Suppl. 7): 5–10. 185. Середенин С.Б. Фармакогенетическая концепция анксиоселективного эффекта. Вестн. РАМН. 1998; 11: 3–9. 186. Воронина Т.А. Спектр фармакологической активности гидазепама и его место среди известных транквилизаторов. Гидазепам. Под ред. С.А.Андронати. Киев: Наукова думка. 1992; с. 63–74. 187. Aupperle RL, Ravindran L, Tankersley D et al. Pregabalin influences insula and amygdala activation during anticipation of emotional images. Neuropsychopharmacol 2011; 36 (7): 1466–77.